Related Experiment Video

Updated: Feb 3, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.3K

Implantable cardioverter-defibrillator in hypertrophic cardiomyopathy

Diego Jimenez Sanchez1, Ignacio Fernández Lozano1

  • 1Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.

Global Cardiology Science & Practice
|November 6, 2018
PubMed

Insights

Implantable cardioverter-defibrillators (ICDs) effectively prevent sudden cardiac death in hypertrophic cardiomyopathy (HCM) patients. New risk models improve identification of high-risk individuals for timely intervention.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Genetics

Background:

  • Sudden cardiac death (SCD) is a major risk in hypertrophic cardiomyopathy (HCM).
  • Implantable cardioverter-defibrillators (ICDs) are effective in preventing SCD in various populations.
  • HCM presents unique challenges for arrhythmia management due to specific cardiac morphology.

Purpose of the Study:

  • To evaluate the efficacy and safety of ICDs in preventing SCD in HCM patients.
  • To assess the effectiveness of current risk stratification strategies and explore novel prediction models.
  • To review perioperative and long-term complications associated with ICDs in HCM.

Main Methods:

  • Review of clinical studies and data on ICD implantation in HCM patients.
  • Analysis of appropriate ICD intervention rates for primary and secondary prevention.
  • Comparison of traditional risk factors with new risk prediction models for SCD in HCM.
  • Evaluation of perioperative and long-term complication data, including inappropriate shocks and device-related issues.

Main Results:

  • ICDs demonstrate high rates of appropriate intervention in HCM patients, successfully terminating life-threatening ventricular arrhythmias.
  • Novel risk prediction models show superiority over traditional methods for identifying high-risk HCM patients.
  • While perioperative complications are comparable to other cardiac devices, long-term data on ICD complications in HCM patients are limited.
  • Subcutaneous ICDs show promise as a safe alternative, but require further long-term investigation.

Conclusions:

  • ICDs are crucial for SCD prevention in HCM, with significant appropriate intervention rates.
  • Improved risk stratification is essential due to the relatively low incidence of SCD in HCM.
  • Further research is needed to fully understand long-term ICD-related complications and optimize therapy in this population.

More Related Videos

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

26.8K
A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring05:54

A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring

Published on: November 29, 2024

2.2K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
490
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
568
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
538
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
442
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
605
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
356